secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirati Therapeutics, Inc. (—)
CIK:        0001576263
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-206176
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirati CEO David Meek departs; Charles Baum interim CEO; Q2 net loss $176.9M, KRAZATI rev $13.4M
--------------------------------------------------------------------------------

- CEO David Meek resigned Aug 7, 2023; founder Charles Baum named interim CEO; Meek remains consultant through Oct 15.
- Q2 net loss $176.9M ($3.04/sh); KRAZATI revenue $13.4M; cash $779.4M; FY23 net cash burn guidance $560-580M.
- Plans Phase 3 adagrasib + pembro in 1L NSCLC TPS≥50% by year-end; CHMP issued negative opinion on conditional MAA.
- MRTX1719 initial data show favorable safety and early activity in MTAP-deleted cancers; Phase 2 planned H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/d499867d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-206176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer